Summit Therapeutics Share Discussion Threads

[hugus maximus] 18/1/2018 08:26

Observation: Re NASDAQ / AIM parity ... as the dollar has lost value against the pound, the MMs currently seem less eager to push the UK £ rate down. For example at close of business last night the NASDAQ was $12 = £1.74 (after one fifth adjustment) .. whereas AIM sits at mid price £1.82.50 this morning.

[chrisatrdg] 16/1/2018 20:16

For those who want to find further background information on Discuva just look at their current twitter account.

[hugus maximus] 15/1/2018 08:55

NASDAQ closed today for Martin Luther King day.

Haven't been here since Christmas and things are looking good. Crossing fingers and toes for some (even small) significant 24 wk improvement in DMD P2 muscle biopsy.

Having taken a look at activity here since New Year, it seems that simple proof of Utrophin Modulation concept may be enough encouragement for Sarepta to buy the DMD project and Summit to sail off into the sunset as a company specialising in antibiotics ... with a much enhanced share price ... "Trebles all round!" (Private Eye quote - though no irony intended)

[waterloo01] 12/1/2018 16:02

$44 TP broker note also rather helps. They certainly have a number options open to them going forward. A lot will depend on DMD results.

[luminoso] 12/1/2018 15:57

Think the MMs must read this board - a mark up !

[luminoso] 12/1/2018 15:32

Sarepta threatening 60 dollars. Seems a bouyant market for biotech at present. Good time to get some decent results out.

[luminoso] 12/1/2018 15:31

There certainly always seems to be a delay in marking the price up on AIM, when nasdaq is rising. Question of disbelief that it will hold maybe ?

[football] 12/1/2018 08:34

There I was thinking just because we was up in the US at the close and a couple of percent after hours that we would be blue today, it seems we only follow US down rather than up

gla

[chrisatrdg] 11/1/2018 21:16

NASDAQ closed at $12.73 & equates to £1.89 using 1.35 US$ to the £ - will be interesting to see what happens on AIM Friday.

[filmster] 11/1/2018 18:05

Thank you. I think i knew that but just hoped it was 4 ha

[filmster] 11/1/2018 17:28

Is nasdaq 5 shares of uk shares or 4? i can't remember.

[waterloo01] 11/1/2018 17:04

Looks to be making a push for $13. New uptrend?

[maxwellsdemon] 10/1/2018 23:01

Edited: Wrong thread.

[luminoso] 10/1/2018 20:11

Well, Let me be the first to say that I invested here for the DMD and that alone !
The passion and commitment to her task of Prof Kay Davies brought me here.
Plus the output of the BOD was unequivocally DMD focussed for many years, in fact until very recently !
DMD was always described as the company maker.
I saw the C Diff project as a way of funding DMD through to P3 and maybe beyond. However reality set in when it was clear that Big Pharma were tired of anti-biotics and saw no real value in them, being as short sighted as me, apparently.
There was going to be no early pay day to progress DMD.
It was really the report by Jim O'Neill on anti-biotics which awoke me to the potential future of our C. Diff drug.
Plus the inexorable rise of Sarepta in defiance of gravity (in the form of test results and efficacy).
Clearly to get as far as they have with their flawed drug, they must be the favoured FDA choice for advancing DMD solutions.
So, sorry Kay, but the future of your work is probably heading across the Atlantic. With their lobbyists and with senators in their pockets, they are no doubt the future of DMD.
Hopefully our results will be good and attract a big cheque.

[abergele] 10/1/2018 18:02

If it keeps rising states side, we could perhaps get some new interest here tomoz
gla lth's

[chrisatrdg] 10/1/2018 17:49

Hi waterloo01 Just about to say the same & it has been a long time coming!

[waterloo01] 10/1/2018 16:57

$12 bucks again. Seems like a long time coming!

[chrisatrdg] 10/1/2018 12:04

I too have always thought that Summits C-Diff drug was the ace in the pack & remember so well when Glyn went through the phase 1 results at an AGM a few years back - he was more than enthusiastic.

[waterloo01] 10/1/2018 10:14

It's what got me invested in the first place as well. Should be an interesting few months.

[tightfist] 10/1/2018 09:39

Hi Waterloo,Many thanks for the link to the Seeking Alpha review; the best summary I have seen of SMMT science and commercial prospects/valuation. Although DMD grabs the headlines I have always been chiefly invested for the C.Diff antibiotic with its broader value to society - we lost a dear friend to C.Diff many years ago.Cheers, tightfist

[chrisatrdg] 09/1/2018 20:01

Sarepta Therapeutics (SRPT) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slideshow:

[abergele] 09/1/2018 18:44

My basis for holding has always been the antibiotic view for C.diff..
a wider treatment of persons rather than the smaller DMD cases..imho..gla lth's

[waterloo01] 09/1/2018 15:41

Interesting as they are basing most of the value on RDZ!

We have conservatively modeled the per share value of each compound and generated a 12-month price target of $44/share. Given the recent price behavior of the stock, the current share price makes a compelling case as a lower risk, high reward investment.

[luminoso] 09/1/2018 14:55

Edit - didn't see someone had already posted seeking alpha story !